Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

American Society of Clinical Oncology (ASCO) - Tập 33 Số 23 - Trang 2516-2522 - 2015
Carla Casulo1, Michelle Byrtek1, Keith Dawson1, Xiaolei Zhou1, Charles M. Farber1, Christopher R. Flowers1, John D. Hainsworth1, Matthew J. Maurer1, James R. Cerhan1, Brian K. Link1, Andrew D. Zelenetz1, Jonathan W. Friedberg1
1Carla Casulo and Jonathan W. Friedberg, University of Rochester, Rochester; Jonathan W. Friedberg, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Byrtek and Keith L. Dawson, Genentech, South San Francisco, CA; Xiaolei Zhou, RTI Health Solutions, Research Triangle Park, NC; Charles M. Farber, Carol G. Simon Cancer Center, Morristown, NJ; Christopher R. Flowers, Emory University, Atlanta, GA; John D. Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Matthew J. Maurer and James R....

Tóm tắt

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the National LymphoCare Study to identify whether prognostic FL factors are associated with early POD and whether patients with early POD are at high risk for death. Patients and Methods In total, 588 patients with stage 2 to 4 FL received first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Two groups were defined: patients with early POD 2 years or less after diagnosis and those without POD within 2 years, the reference group. An independent validation set, 147 patients with FL who received first-line R-CHOP, was analyzed for reproducibility. Results Of 588 patients, 19% (n = 110) had early POD, 71% (n = 420) were in the reference group, 8% (n = 46) were lost to follow-up, and 2% (n = 12) died without POD less than 2 years after diagnosis. Five-year overall survival was lower in the early-POD group than in the reference group (50% v 90%). This trend was maintained after we adjusted for FL International Prognostic Index (hazard ratio, 6.44; 95% CI, 4.33 to 9.58). Results were similar for the validation set (FL International Prognostic Index–adjusted hazard ratio, 19.8). Conclusion In patients with FL who received first-line R-CHOP, POD within 2 years after diagnosis was associated with poor outcomes and should be further validated as a standard end point of chemoimmunotherapy trials of untreated FL. This high-risk FL population warrants further study in directed prospective clinical trials.

Từ khóa


Tài liệu tham khảo

10.6004/jnccn.2011.0046

10.1200/JCO.2005.03.3696

10.1200/JCO.2005.03.1674

10.1200/JCO.2005.04.503

10.1182/blood-2013-03-491514

10.1182/blood-2004-08-3175

10.1200/JCO.2006.06.4618

10.1200/JCO.2012.45.0866

10.1182/blood-2013-11-531327

10.1016/S0140-6736(12)61763-2

10.1200/JCO.2012.42.4101

10.1016/S0140-6736(10)62175-7

10.1182/blood-2003-12-4434

10.1200/JCO.2008.21.3991

10.1056/NEJM199309303291402

10.1182/asheducation-2013.1.561

10.1056/NEJMoa041869

10.1200/JCO.1995.13.1.140

10.1200/JCO.2009.22.7819

10.1200/JCO.2009.25.0852

10.1200/JCO.2008.18.1495

10.1200/JCO.2012.48.3990

10.1137/1114019

10.1200/JCO.2007.13.5376

10.1016/j.bbmt.2007.04.009

10.1200/JCO.2012.47.1862

10.1038/bmt.2013.83

10.3324/haematol.2010.030320

10.1200/JCO.2011.38.6359

10.1200/JCO.2013.49.6125

10.1200/JCO.2005.01.6071

10.1093/jnci/djt269

10.1200/JCO.2013.51.5866

10.1182/blood-2008-02-140616

10.1182/blood-2008-05-154013

10.1200/JCO.2008.16.4061